Literature DB >> 9203026

Immunotherapy for Behçet's disease.

M Mochizuki1.   

Abstract

Behçet's disease is an inflammatory disorder affecting many organs including the eye and one of the most common sight-threatening causes in countries around the Mediterranean basin and in the Asia including Japan, Korea and China. A number of clinical and laboratory findings suggest the significant involvement of the immune alterations in the pathophysiology and the pathogenic mechanisms of Behçet's disease. The immune alterations demonstrated in the disease include the alteration of the T cell circuitry and abnormal functions of the leukocyte. Because immunologic processes are believed to be in the chain of events in the manifestation of Behçet's disease, various agents capable of modulating the immune responses have been used to treat the disease. These drugs include corticosteroids, colchicine, cytotoxic agents, and immunophilin ligands (cyclosporine and FK506). This paper reviews the experimental and clinical investigations to analyze the immunopharmacological activities of these immunosuppressive agents in animal models and in patients with Behçet's disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9203026     DOI: 10.3109/08830189709116844

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  9 in total

Review 1.  Behçet's disease: immunopathologic and therapeutic aspects.

Authors:  Robert Meador; George Ehrlich; Joan M Von Feldt
Journal:  Curr Rheumatol Rep       Date:  2002-02       Impact factor: 4.592

2.  T-bet expression is upregulated in active Behçet's disease.

Authors:  B Li; P Yang; H Zhou; Z Zhang; C Xie; X Lin; X Huang; A Kijlstra
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

3.  Clinical course of patients with Behçet's uveitis following discontinuation of infliximab therapy.

Authors:  Tatsushi Kawaguchi; Yuko Kawazoe; Koju Kamoi; Masaru Miyanaga; Hiroshi Takase; Sunao Sugita; Manabu Mochizuki
Journal:  Jpn J Ophthalmol       Date:  2013-10-16       Impact factor: 2.447

4.  [Behcet's disease--ophthalmological and general aspects: Part 2: Therapy].

Authors:  U Pleyer; D Hazirolan; S Winterhalter; N Stübiger
Journal:  Ophthalmologe       Date:  2013-03       Impact factor: 1.059

5.  Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy.

Authors:  Atsushi Yoshida; Toshikatsu Kaburaki; Kimiko Okinaga; Mitsuko Takamoto; Hidetoshi Kawashima; Yujiro Fujino
Journal:  Jpn J Ophthalmol       Date:  2012-10-02       Impact factor: 2.447

6.  Effects of the Concomitant Use of Low-dose Clarithromycin with an Anti-TNFα Antibody in a Patient with Intestinal Behçet Disease.

Authors:  Junichi Iwamoto; Masashi Murakami; Naoki Konishi; Tadakuni Monma; Hajime Ueda; Shoichiro Yara; Takeshi Hirayama; Tadashi Ikegami; Akira Honda; Yasushi Matsuzaki
Journal:  Intern Med       Date:  2017-11-01       Impact factor: 1.271

7.  A Strategy for Personalized Treatment of iPS-Retinal Immune Rejections Assessed in Cynomolgus Monkey Models.

Authors:  Shota Fujii; Sunao Sugita; Yoko Futatsugi; Masaaki Ishida; Ayaka Edo; Kenichi Makabe; Hiroyuki Kamao; Yuko Iwasaki; Hirokazu Sakaguchi; Yasuhiko Hirami; Yasuo Kurimoto; Masayo Takahashi
Journal:  Int J Mol Sci       Date:  2020-04-27       Impact factor: 5.923

8.  An unusual case of Behcet disease with posterior scleritis: A case report.

Authors:  Chihiro Yanagida; Yoshihiko Usui; Jun-Ichi Sakai; Hiroshi Goto
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

9.  Current trends in the management of ocular symptoms in Adamantiades-Behçet's disease.

Authors:  Fouad R Zakka; Peter Y Chang; Gian P Giuliari; C Stephen Foster
Journal:  Clin Ophthalmol       Date:  2009-10-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.